Trials / Unknown
UnknownNCT00637442
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University Hospital, Bonn · Academic / Other
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reminyl retard | retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-12-01
- First posted
- 2008-03-18
- Last updated
- 2010-11-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00637442. Inclusion in this directory is not an endorsement.